Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Cytisine Bioavailability
NCT03268343Phase 1Completed
- Sponsor
- Achieve Life Sciences
- Start
- Aug 2017
- Primary completion
- Aug 2017
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cytisinicline in nicotine dependence (2 arms), sponsored by Achieve Life Sciences. Primary endpoints: Maximum Observed Plasma Concentration at 24 hours and Total Area Under the Curve From Time Zero to Infinity at 24 hours. Started Aug 2017; status: completed.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT03268343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03268343.